<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794659</url>
  </required_header>
  <id_info>
    <org_study_id>PN-201-22</org_study_id>
    <nct_id>NCT05794659</nct_id>
  </id_info>
  <brief_title>Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer</brief_title>
  <acronym>Cornerstone4</acronym>
  <official_title>A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston Sci. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aston Sci. Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant&#xD;
      therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed&#xD;
      homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking&#xD;
      surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo&#xD;
      with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will comprise a screening period of -28 Days prior to initiation of study treatment&#xD;
      (Day 1); an enrollment period of 24 months; the treatment duration will be approximately of 5&#xD;
      months.&#xD;
&#xD;
      The study will evaluate whether the addition of AST-201/rhuGM-CSF to the standard adjuvant&#xD;
      chemotherapy will extend the Progression Free Survival(PFS) rate. Survival follow-up will be&#xD;
      performed every 3 months (±14 days) after the End of treatment (EOT) visit for 2 years after&#xD;
      randomization and every 6 months (±28 days) thereafter until disease progression or death&#xD;
      from any cause or withdrawal of consent whichever comes first. Survival follow-up visits will&#xD;
      be conducted by telephone, in-person visit, or chart review. The end of study (EOS) is&#xD;
      defined as 2 years after the date of last patient enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2023</start_date>
  <completion_date type="Anticipated">August 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single blind, randomized, placebo-controlled, multicenter, phase 2 clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>overall study duration (approximately 48 months)</time_frame>
    <description>the time from the date of randomization to disease progression, or death from any cause whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year PFS rate</measure>
    <time_frame>24months from the first dose of AST-301 administration</time_frame>
    <description>proportion of patients alive without disease progression or death at two years after the randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>overall study duration (approximately 48 months)</time_frame>
    <description>the time from the date of randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST-201 specific immunogenicity by Interferon gamma (IFN-gamma) enzyme-linked immunospot (ELISpot )</measure>
    <time_frame>17months</time_frame>
    <description>AST-201 specific IFN-gamma ELISpot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse events as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0)</measure>
    <time_frame>5 months</time_frame>
    <description>Adverse events (AEs) Treatment-emergent adverse events (TEAEs) Serious adverse events (SAEs) Vital signs Physical examination Eastern Cooperative Oncology Group (ECOG) performance status Electrocardiogram (ECG) test Laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Advanced Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>AST-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AST-201 with rhuGM-CSF (3-week interval, 3 cycles in total)&#xD;
Standard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)&#xD;
* Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with rhuGM-CSF (3-week interval, 3 cycles in total)&#xD;
Standard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)&#xD;
*Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AST-201</intervention_name>
    <description>i.d. (3-week interval, 3 cycles in total)</description>
    <arm_group_label>AST-301</arm_group_label>
    <other_name>pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>3-week interval, 6 cycles in total</description>
    <arm_group_label>AST-301</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>3-week interval, 6 cycles in total</description>
    <arm_group_label>AST-301</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>i.d. (3-week interval, 3 cycles in total)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline (USP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)</intervention_name>
    <description>i.d. (3-week interval, 3 cycles in total)</description>
    <arm_group_label>AST-301</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sargramostim</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed stage III (FIGO classification) epithelial ovarian cancer including&#xD;
             primary peritoneal cancer, fallopian-tube cancer&#xD;
&#xD;
          -  Has received upfront surgery and optimally debulked(a residual tumor less than 1 cm)&#xD;
&#xD;
          -  Can start adjuvant therapy within 6 weeks of debulking surgery&#xD;
&#xD;
          -  Has Homologous Recombination Proficiency (HRP) tumor defined by FDA-approved testing&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Demonstrates adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of hypersensitivity or other contraindications to rhuGM-CSF&#xD;
&#xD;
          -  Has a history of active malignancy ≤5 years prior to first administration of&#xD;
             investigational drug except for adequately treated non-melanoma skin cancer or&#xD;
             epithelial carcinoma without evidence of disease&#xD;
&#xD;
          -  Is on immune suppression therapy or has a history of immune suppression therapy ≤4&#xD;
             weeks prior to the first administration of investigational drugs&#xD;
&#xD;
          -  Has active or prior autoimmune disease or inflammatory disease&#xD;
&#xD;
          -  Has active infectious disease including tuberculosis, hepatitis B, hepatitis C or&#xD;
             human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive children within the projected&#xD;
             duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyunwon Shin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>hyunwon.shin@astonsci.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunwon Shin, MD, PhD</last_name>
    <phone>+82-2-2038-2347</phone>
    <email>hyunwon.shin@astonsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eunkyo Joung, MD, CMO</last_name>
    <phone>+82-2-2038-2347</phone>
    <email>eunkyo.joung@astonsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John B. Liao, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 7, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer vaccine</keyword>
  <keyword>phase 2 study</keyword>
  <keyword>Advanced ovarian cancer</keyword>
  <keyword>homologous-recombination proficient (HRP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

